SciClone Pharmaceuticals Inc
(NASDAQ: SCLN)
+0.20
+4.19%
| Exchange: | NASDAQ |
| Stock: | SciClone Pharmaceuticals, Inc. |
| Industry: | Drug Manufacturers - Other |
| Employees: | 870 |
| SciClone Pharmaceuticals, Inc. (SciClone) is a specialty pharmaceutical company. The Company has a product portfolio of therapies for oncology, infectious diseases, cardiovascular, urological, respiratory and central nervous system disorders. The Company’s main product is ZADAXIN (thymalfasin), which is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers. In China, thymalfasin is also included in the treatment guidelines issued by the Ministry of Health for liver cancer. SciClone’s marketed portfolio also includes Depakine, the prescribed broad-spectrum anti-convulsant in China; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a hypnotic for the short-term treatment of insomnia (marketed as Ambien in the United States), and Aggrastat, an intervention cardiology product. On April 18, 2011, the Company acquired NovaMed Pharmaceuticals, Inc. |
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.
